Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cecilie Totland

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Journal of Neuroimmunology|March 6, 2007
Hu and Yo antibodies have heterogeneous avidityCecilie Totland, Jan Aarseth, Christian Vedeler
Frontiers in Neurology|October 11, 2021
CRMP5 Antibodies-Diagnostic ChallengesCecilie Totland, Mette Haugen, Christian Vedeler
Neurology(R) Neuroimmunology & Neuroinflammation|February 3, 2021
Paraneoplastic Cerebellar Degeneration: The Importance of Including CDR2L as a Diagnostic MarkerIda Herdlevær, Mette Haugen, Kibret Mazengia, et al.
Oncotarget|May 31, 2018
Expression of the onconeural protein CDR1 in cerebellum and ovarian cancerCecilie Totland, Torbjørn Kråkenes, Kibret Mazengia, et al.
Cancer Immunology, Immunotherapy : CII|August 15, 2009
Antibody to CCDC104 is associated with a paraneoplastic antibody to CDR2 (anti-Yo)Cecilie Totland, Geir Bredholt, Mette Haugen, et al.
European Journal of Neurology|March 13, 2023
A cerebellar degeneration-related protein 2-like cell-based assay for anti-Yo detection in patients with paraneoplastic cerebellar degenerationKjell Inge Erikstad, Ida Herdlevaer, Elise Peter, et al.
Cancer Immunology, Immunotherapy : CII|June 5, 2013
Avidity of onconeural antibodies is of clinical relevanceCecilie Totland, Ming Ying, Mette Haugen, et al.
BMC Cancer|May 27, 2024
Multi-omics profiling reveals dysregulated ribosome biogenesis and impaired cell proliferation following knockout of CDR2LEirik Tveit Solheim, Yola Gerking, Torbjørn Kråkenes, et al.
Annals of Clinical and Translational Neurology|October 30, 2024
Altered exosomal miRNA profiles in patients with paraneoplastic cerebellar degenerationEirik Tveit Solheim, Liv Cecilie Vestrheim Thomsen, Line Bjørge, et al.
Cancer Immunology, Immunotherapy : CII|November 17, 2010
CDR2 antigen and Yo antibodiesCecilie Totland, Nina K Aarskog, Tilo W Eichler, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Journal of Neuroimmunology|March 6, 2007
Hu and Yo antibodies have heterogeneous avidityCecilie Totland, Jan Aarseth, Christian Vedeler
Frontiers in Neurology|October 11, 2021
CRMP5 Antibodies-Diagnostic ChallengesCecilie Totland, Mette Haugen, Christian Vedeler
Neurology(R) Neuroimmunology & Neuroinflammation|February 3, 2021
Paraneoplastic Cerebellar Degeneration: The Importance of Including CDR2L as a Diagnostic MarkerIda Herdlevær, Mette Haugen, Kibret Mazengia, et al.
Oncotarget|May 31, 2018
Expression of the onconeural protein CDR1 in cerebellum and ovarian cancerCecilie Totland, Torbjørn Kråkenes, Kibret Mazengia, et al.
Cancer Immunology, Immunotherapy : CII|August 15, 2009
Antibody to CCDC104 is associated with a paraneoplastic antibody to CDR2 (anti-Yo)Cecilie Totland, Geir Bredholt, Mette Haugen, et al.
European Journal of Neurology|March 13, 2023
A cerebellar degeneration-related protein 2-like cell-based assay for anti-Yo detection in patients with paraneoplastic cerebellar degenerationKjell Inge Erikstad, Ida Herdlevaer, Elise Peter, et al.
Cancer Immunology, Immunotherapy : CII|June 5, 2013
Avidity of onconeural antibodies is of clinical relevanceCecilie Totland, Ming Ying, Mette Haugen, et al.
BMC Cancer|May 27, 2024
Multi-omics profiling reveals dysregulated ribosome biogenesis and impaired cell proliferation following knockout of CDR2LEirik Tveit Solheim, Yola Gerking, Torbjørn Kråkenes, et al.
Annals of Clinical and Translational Neurology|October 30, 2024
Altered exosomal miRNA profiles in patients with paraneoplastic cerebellar degenerationEirik Tveit Solheim, Liv Cecilie Vestrheim Thomsen, Line Bjørge, et al.
Cancer Immunology, Immunotherapy : CII|November 17, 2010
CDR2 antigen and Yo antibodiesCecilie Totland, Nina K Aarskog, Tilo W Eichler, et al.
Pageof 1